- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04518345
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia
A Phase 1b/2 Study of TP-0903 in Patients With Acute Myeloid Leukemia and FLT3 Mutations
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine a tolerable dose of dubermatinib (TP-0903) monotherapy for relapsed/refractory patients with FLT3 acute myeloid leukemia (AML).
II. To determine the maximum tolerated dose (MTD) of TP-0903 with azacitidine in untreated unfit patients with FLT3 AML.
III. To determine the complete remission (CR) or complete remission with partial hematologic recovery (CRh) rate following induction therapy with TP-0903 in relapsed/refractory patients or TP-0903 with azacitidine therapy in untreated unfit patients with FLT3 AML.
SECONDARY OBJECTIVES:
I. To determine the toxicity profile of TP-0903 as a single agent and in combination with or azacitidine.
II. To determine disease-free survival for patients achieving CR/CRh in each cohort.
III. To determine overall survival for patients in each cohort. IV. To determine the proportion of patients who go to transplant.
EXPLORATORY OBJECTIVES:
I. To conduct pharmacokinetic studies of TP-0903 alone and in combination with azacitidine.
II. To examine changes in circulating AXL, Gas6, FLT3 ligand, and other cytokines/chemokines by TP-0903.
III. To determine the impact of TP-0903 on the inhibition of kinase signaling (AXL, FLT3, STAT5, AURKA), and metabolomics in AML cells.
IV. To determine differentially expressed genes in bone marrow stromal cells and AML cells upon TP-0903 treatment.
V. To examine sensitivity and resistance patterns associated with TP-0903 by genomic, epigenomic, and transcriptomic profiling.
OUTLINE: This is a phase Ib, dose-escalation study of dubermatinib followed by a phase II study.
(FLT3 AML WITH RELAPSED/REFRACTORY DISEASE):
INDUCTION: Patients receive dubermatinib orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission.
After completion of study treatment, patients are followed up followed every 3 months for up to 2 years from registration and then every 6 months for up to 5 years from registration.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with AML and the presence of FLT3-ITD mutation
- Patients with secondary AML or therapy related disease (t-AML) are eligible
- If the patient has co-morbid medical illness, life expectancy attributed to this must be greater than 6 months
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Total bilirubin < 2.0mg/dL unless due to Gilbert's disease
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal
- Creatinine (Cr) clearance > 50 mL/min by Cockcroft-Gault calculation
- New York Heart Association (NYHA) Congestive Heart Failure (CHF) class II or better
- Cardiac ejection fraction ≥40%
- Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose
- Ability to understand and willingness to sign the written informed consent document
- Human immunodeficiency virus (HIV) infection without history of acquired immunodeficiency syndrome (AIDS) and sufficiently high CD4 cells (> 400/mm^3) and low HIV viral loads (< 30,000 copies/ml plasma) not requiring anti-HIV therapy are eligible
Exclusion Criteria:
- Patients with acute promyelocytic leukemia
- Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Treatment with hydoxyurea is permitted during cycle 1 to maintain white blood cell (WBC) < 40,000/uL
- Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
- Patients with active central nervous system (CNS) malignancy
- Major surgery within 2 weeks before day 1
- Uncontrolled active infection. Patients with infection requiring parenteral antibiotics are eligible if the infection is controlled
- Patients with significantly diseased or obstructed gastrointestinal tract
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, myocardial infarction within 6 months prior to enrollment, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant
- Patients with serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Pregnant women or women who are breastfeeding are excluded from this study. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women
- Patients with advanced malignant solid tumors
- Patients who are not able to swallow capsules or tablets
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (dubermatinib)
FLT3 AML WITH RELAPSED/REFRACTORY DISEASE: INDUCTION: Patients receive dubermatinib PO QD on days 1-21. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients with clinical or hematologic response and not transplant eligible may continue dubermatinib until loss of response/clinical benefit. Patients with clinical or hematologic response and transplant eligible may continue dubermatinib until one week prior to admission. |
Given IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose of dubermatinib (TP-0903)
Time Frame: Up to 28 days
|
Determine a tolerable dose of TP-0903 monotherapy for relapsed/refractory patients with FLT3 AML.
|
Up to 28 days
|
Composite complete response (CR) rate
Time Frame: Up to 5 years post registration
|
Will calculate the composite CR rate (complete remission [CR]/complete remission with incomplete count recovery [CRh) defined according to the 2017 European LeukemiaNet Acute Myeloid Leukemia recommendation.
|
Up to 5 years post registration
|
Composite CR rate with partial hematologic recovery (CRh) rate
Time Frame: through study completion, an average of 1 year
|
Will calculate the composite CR rate (CR/CRh), defined according to the International Working Group criteria and assessed at the end of induction.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-free survival
Time Frame: From the date of first CR/CRh until the first date of relapse/progression or death from any cause, assessed up to 5 years post registration
|
Will be summarized by the Kaplan-Meier method to determine disease-free survival for patients achieving complete response CR/CRh in each cohort of the study.
|
From the date of first CR/CRh until the first date of relapse/progression or death from any cause, assessed up to 5 years post registration
|
The Number of patients who proceed to transplant
Time Frame: Up to 5 years post registration
|
The number of patients who got to transplant
|
Up to 5 years post registration
|
Overall survival
Time Frame: From the treatment start date until the date of death from any cause or date last known alive, assessed up to 5 years post registration
|
Will be summarized by the Kaplan-Meier method.
|
From the treatment start date until the date of death from any cause or date last known alive, assessed up to 5 years post registration
|
Maximum grade of each type of adverse event
Time Frame: Up to 5 years post registration
|
Will be recorded for each patient and summarized.
|
Up to 5 years post registration
|
Incidence of treatment-related adverse events
Time Frame: Up to 5 years post registration
|
Treatment-related adverse events, defined as possibly, probably or definitely related to study treatment per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 will be summarized separately.
|
Up to 5 years post registration
|
Tolerability of TP-0903
Time Frame: Up to 5 years post registration
|
Reasons for treatment discontinuation and number of TP-0903 cycles received will be summarized and used to assess tolerability.
|
Up to 5 years post registration
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Plasma Concentration (Cmax) pharmacokinetics (PK)
Time Frame: Up to 5 years post registration
|
Initial analysis of plasma PK data will include standard compartmental and noncompartmental methods.
Descriptive statistics including means, standard deviations, and frequencies will be computed for all variables.
Relationships between continuous variables will be performed using standard linear correlation and linear regression.
Relationships between PK parameters such as maximum concentration with response will be performed using standard t-tests or Wilcoxon rank sum tests and illustrated using boxplots or other graphical displays.
|
Up to 5 years post registration
|
Area under the plasma concentration (AUC) pharmacokinetics (PK)
Time Frame: Up to 5 years post registration
|
Initial analysis of plasma PK data will include standard compartmental and noncompartmental methods.
Descriptive statistics including means, standard deviations, and frequencies will be computed for all variables.
Relationships between continuous variables will be performed using standard linear correlation and linear regression.
Relationships between PK parameters such as area under curve with response will be performed using standard t-tests or Wilcoxon rank sum tests and illustrated using boxplots or other graphical displays.
|
Up to 5 years post registration
|
Changes in cytokines/chemokines
Time Frame: Up to 5 years post registration
|
Differences in cytokines/chemokines will be evaluated using paired t-tests or Wilcoxon signed rank tests.
Values will be log transformed as appropriate to reflect biologic plausibility.
Cytokines/chemokines to be measured include: AXL, GAS6, FLT3 ligand, GM-CSF, IL-6, IL-8, RANTES, MIP-1α, MCP-1, sCD40L, EGF, VEGF
|
Up to 5 years post registration
|
Effect of TP-0903 on inhibition of phospho-protein expression Effect of TP-0903 on inhibition of phospho-protein expression Effect of TP-0903 on inhibition of phospho-protein expression Impact of TP-0903 on kinase signaling
Time Frame: Up to 5 years post registration
|
Percent inhibition of phospho-protein expression in AML cells.
Phospho-proteins to be measured include: phospho-FLT3, phospho-STAT5, phospho-AURKA/B, phosho-AXL
|
Up to 5 years post registration
|
Patterns of sensitivity and resistance
Time Frame: Up to 5 years post registration
|
Mutational status in AML cells will be determined in samples at baseline and during treatment.
Mutations in genes with single nucleotide changes and indels at variant allele frequency (VAF) >0.1 will be reported.
Mutations with decreasing VAF represent sensitivity, and increasing VAF represent resistance.
|
Up to 5 years post registration
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Uma Borate, MD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-19229
- NCI-2020-04292 (REGISTRY: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Azacitidine
-
Shandong Provincial HospitalUnknownMyelodysplastic Syndromes,Acute Myeloid LeukemiaChina
-
TJ Biopharma Co., Ltd.Recruiting
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Celgene CorporationCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)Australia
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
Navy General Hospital, BeijingRecruitingRefractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin LymphomaChina
-
University of BirminghamRecruitingAcute Myeloid Leukemia | MyelodysplasiaUnited Kingdom
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
Bristol-Myers SquibbRecruitingMyelodysplastic SyndromesUnited States, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Canada, Czechia, Korea, Republic of, Poland, Turkey, France
-
CelgeneCompletedMyelodysplastic SyndromesUnited States